Company Type: BioTech, Diagnostics

A complete cure for fibrosis, including idiopathic pulmonary fibrosis (IPF), still depends on organ transplantation. While approved standard-of-care drugs for IPF exist, they only slow the disease's progression without halting or reversing it. As a result, patients with IPF and their families are eagerly awaiting a potential curative treatment. The introduction of such a drug could swiftly reshape the standard care market. Antibody Therapeutics aim to position our antibody drug within Japan’s $400 million IPF treatment market.

Company Type: BioTech, Oncology

PURMX leverages a novel functional screening platform centered on senescence-associated microRNAs, which are present in normal cells but absent in cancer cells. Since 2021, we have been developing innovative nucleic acid medicines to address the needs of patients with rare cancers.

PURMX is the only company in the world conducting clinical trials with miRNA therapeutics.

Company Type: BioTech, Diagnostics, AI, Oncology

Setolab is developing a test that can detect 13 types of cancer at very early stages using miRNA in blood samples. Although tests for early detection have been commercialized, they have proven to be expensive and inadequately accurate. Setolab, in collaboration with a university hospital in Japan, is making significant strides in accurately detecting 13 types of cancers. The company is developing a PCR-based test targeting specific miRNAs, taking advantage of PCR's cost-effectiveness and convenience as a diagnostic method.